Page 1 | Search Results | Blood | American Society of Hematology

1-6 of 6

Sort by

Sort Order Select

Journal Articles

Identification of Specific Hnrnps As Novel Therapeutic Targets and Responsive Indicators of KPT330 (selinexor) in Leukemia

Adam Cloe, MD PhD, Li Chen, MD PhD, Yuan Li, MD, Hongtao Liu, MD PhD, Jason X. Cheng, MD PhD

Blood (2016) 128 (22): 1657.

https://doi.org/10.1182/blood.V128.22.1657.1657

Published: 2016

Journal Articles

Bromodomain and Extra-Terminal Motif Proteins (BETs) Mediate 5-Azacitidine Resistance in Myeloid Leukemia through Recruitment of an Active RNA Polymerase II Complex

Li Chen, MD PhD, Yuan Li, MD, Ming Yue, PhD, Adam Cloe, MD PhD, Michelle M. Le Beau, PhD, Chuan He, PhD, Richard A. Larson, MD, James W. Vardiman, MD, Jason X. Cheng, MD PhD

Blood (2016) 128 (22): 746.

https://doi.org/10.1182/blood.V128.22.746.746

Published: 2016

Journal Articles

Multiple Myeloma Derived Factors Generate Tolerogenic Dendritic Cells by Activation of STAT3: A Potential Target for Immunotherapy.

Yaser Homsi, MD, Li Chen, MD, Shuhong Zhang, PhD, Jing Liang, Attaya Suvannasankha, MD, Rafat Abonour, MD., Sherif Farag, MD, PhD

Blood (2009) 114 (22): 3031.

https://doi.org/10.1182/blood.V114.22.3031.3031

Published: 2009

Journal Articles

The Novel Aurora Kinase Inhibitor ENMD-2076 Has Potent Single Agent Activity against Multiple Myeloma (MM) in Vitro and in Vivo , and Shows Synergistic Activity in Combination with Lenalidomide

Xiaojing Wang, PhD, Anthony L. Sinn, Attaya Suvannasankha, MD, Colin D. Crean, Li Chen, MD, Shuhong Zhang, PhD, Jing Liang, MD, Genglin Zhang, Karen E. Pollok, PhD, Rafat Abonour, MD, Carolyn Sidor, MD, Mark R. Bray, PhD, Sherif S. Farag, MD, PhD

Blood (2008) 112 (11): 3660.

https://doi.org/10.1182/blood.V112.11.3660.3660

Published: 2008

Journal Articles

Amplification and Mutation of PSMB5 Gene in Bortezomib Resistant Lymphoblastic Leukemia Cells Derived from Jurkat Line.

Shuqing Lu, MD, PhD, Jianmin Wang, MD, Jianmin Yang, MD/Ph.D, Shenglan Gong, MD, Hong Zhou, MD, Li Chen, MD/Ph.D, Xianmin Song, MD/Ph.D

Blood (2007) 110 (11): 2373.

https://doi.org/10.1182/blood.V110.11.2373.2373

Published: 2007

Journal Articles

Unlike Inactivating PTEN Mutations, Pharmacological Inhibition of PTEN Does Not Increase the Sensitivity of Multiple Myeloma Cells to Inhibition of the PI3K/Akt/mTOR Pathway.

Xiaojing Wang, PhD, Shuhong Zhang, Ph.D, Xiaodong Peng, Ph.D, Joe Garlich, Ph.D, Li Chen, MD, Jing Liang, MD, Sherif Shafik Farag, MD, Ph.D

Blood (2007) 110 (11): 4785.

https://doi.org/10.1182/blood.V110.11.4785.4785

Published: 2007

Update search

NARROW

Publications

Format

Article Type

Topics

Date

Availability

Identification of Specific Hnrnps As Novel Therapeutic Targets and Responsive Indicators of KPT330 (selinexor) in Leukemia

Bromodomain and Extra-Terminal Motif Proteins (BETs) Mediate 5-Azacitidine Resistance in Myeloid Leukemia through Recruitment of an Active RNA Polymerase II Complex

Multiple Myeloma Derived Factors Generate Tolerogenic Dendritic Cells by Activation of STAT3: A Potential Target for Immunotherapy.

The Novel Aurora Kinase Inhibitor ENMD-2076 Has Potent Single Agent Activity against Multiple Myeloma (MM) in Vitro and in Vivo , and Shows Synergistic Activity in Combination with Lenalidomide

Amplification and Mutation of PSMB5 Gene in Bortezomib Resistant Lymphoblastic Leukemia Cells Derived from Jurkat Line.

Unlike Inactivating PTEN Mutations, Pharmacological Inhibition of PTEN Does Not Increase the Sensitivity of Multiple Myeloma Cells to Inhibition of the PI3K/Akt/mTOR Pathway.

Email alerts

ASH Publications

American Society of Hematology

Update search

Identification of Specific Hnrnps As Novel Therapeutic Targets and Responsive Indicators of KPT330 (selinexor) in Leukemia

Bromodomain and Extra-Terminal Motif Proteins (BETs) Mediate 5-Azacitidine Resistance in Myeloid Leukemia through Recruitment of an Active RNA Polymerase II Complex

Multiple Myeloma Derived Factors Generate Tolerogenic Dendritic Cells by Activation of STAT3: A Potential Target for Immunotherapy.

The Novel Aurora Kinase Inhibitor ENMD-2076 Has Potent Single Agent Activity against Multiple Myeloma (MM) in Vitro and in Vivo , and Shows Synergistic Activity in Combination with Lenalidomide

Amplification and Mutation of PSMB5 Gene in Bortezomib Resistant Lymphoblastic Leukemia Cells Derived from Jurkat Line.

Unlike Inactivating PTEN Mutations, Pharmacological Inhibition of PTEN Does Not Increase the Sensitivity of Multiple Myeloma Cells to Inhibition of the PI3K/Akt/mTOR Pathway.

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only